Soleus Capital Discloses Significant Stake in C4 Therapeutics

Ticker: CCCC · Form: SC 13G · Filed: Feb 5, 2024 · CIK: 1662579

C4 Therapeutics, Inc. SC 13G Filing Summary
FieldDetail
CompanyC4 Therapeutics, Inc. (CCCC)
Form TypeSC 13G
Filed DateFeb 5, 2024
Risk Levellow
Pages8
Reading Time10 min
Key Dollar Amounts$0.0001
Sentimentbullish

Complexity: simple

Sentiment: bullish

Topics: institutional-ownership, beneficial-ownership, biotech

TL;DR

**Soleus Capital just bought a chunk of C4 Therapeutics, signaling institutional interest.**

AI Summary

Soleus Capital Master Fund, L.P., a Cayman Islands-based investment fund, reported beneficial ownership of C4 Therapeutics, Inc. common stock as of January 26, 2024. This filing indicates Soleus Capital has become a significant shareholder, potentially signaling their belief in the company's future prospects. For investors, this matters because a large institutional investment can be seen as a vote of confidence, potentially attracting more attention and capital to C4 Therapeutics.

Why It Matters

This filing reveals a new institutional investor, Soleus Capital Master Fund, L.P., has taken a position in C4 Therapeutics, which could influence market perception and future stock performance.

Risk Assessment

Risk Level: low — This filing is a standard disclosure of beneficial ownership and does not inherently present a direct risk to investors.

Analyst Insight

A smart investor would research Soleus Capital's investment strategy and track record to understand their rationale for investing in C4 Therapeutics, and then evaluate C4 Therapeutics' fundamentals and pipeline to see if it aligns with their own investment thesis.

Key Players & Entities

  • Soleus Capital Master Fund, L.P. (company) — reporting person and beneficial owner
  • C4 Therapeutics, Inc. (company) — subject company (issuer)
  • Guy Levy (person) — group member
  • Soleus Capital Group, LLC (company) — group member
  • Soleus Capital, LLC (company) — group member
  • Cayman Islands (company) — place of organization for Soleus Capital Master Fund, L.P.

FAQ

What is the CUSIP number for C4 Therapeutics, Inc. common stock mentioned in this filing?

The CUSIP number for C4 Therapeutics, Inc. common stock is 12529R107, as stated in the filing.

When was the event date that triggered the filing of this Schedule 13G?

The date of the event which required the filing of this statement was January 26, 2024.

Which rule under the Securities Exchange Act of 1934 was checked for this Schedule 13G filing?

The appropriate box checked to designate the rule pursuant to which this Schedule is filed is Rule 13d-1(c).

What is the state of incorporation for C4 Therapeutics, Inc.?

C4 Therapeutics, Inc. is incorporated in DE (Delaware), according to the company data in the filing.

What is the business address listed for Soleus Capital Master Fund, L.P.?

The business address for Soleus Capital Master Fund, L.P. is 104 Field Point Road, 2nd Floor, Greenwich, CT 06830.

Filing Stats: 2,499 words · 10 min read · ~8 pages · Grade level 10 · Accepted 2024-02-05 10:24:28

Key Financial Figures

  • $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o

Filing Documents

If this statement is filed pursuant to §§240.13d-1(b)

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J). (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Ownership

Item 4. Ownership. Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G. Master Fund held, as of the close of business on January 26, 2024, an aggregate of 2,555,996 shares of the common stock of the Issuer. As the general partner of Master Fund, Soleus Capital, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital, LLC, Soleus Capital Group, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital Group, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Capital, LLC or Soleus Capital Group, LLC is the beneficial owner of the shares of the common stock of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein. 7

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class Not applicable.

Ownership of More than Five Percent on Behalf of Another

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.

Identification and Classification of the Subsidiary Which

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Certification

Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 8 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Date : February 5, 2024 Soleus Capital Master Fund, L.P. By: Soleus Capital, LLC, its General Partner By: Soleus Capital Group, LLC, its Managing Manager By: /s/ Guy Levy Name: Guy Levy Title: Managing Member Date : February 5, 2024 Soleus Capital, LLC By: Soleus Capital Group, LLC, its Managing Manager By: /s/ Guy Levy Name: Guy Levy Title: Managing Member Date : February 5, 2024 Soleus Capital Group, LLC By: /s/ Guy Levy Name: Guy Levy Title: Managing Member Date : February 5, 2024 /s/ Guy Levy Name: Guy Levy Footnotes: Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) 9 EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended. It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of

View Full Filing

View this SC 13G filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.